Ovarian Cancer

Chirag Shah, MD, MPH, discusses platinum sensitivity vs resistance impact treatment selection in subsequent lines of therapy.

An expert in gynecologic oncology reviews the PRIMA and NOVA clinical trials and discusses their implications for the management of ovarian cancer.

Chirag Shah, MD, MPH, provides key insights into factors to consider when counseling patients with ovarian cancer on the available treatment options for maintenance therapy.

Key opinion leader in obstetrics and gynecology Chirag Shah, MD, MPH, discusses best practices for molecular testing and genetic counseling for patients with newly diagnosed or relapsed ovarian cancer.

Chirag Shah, MD, MPH shares insight into factors influencing the prognosis of patients with ovarian cancer.

In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.

In phase 1b trial, treatment with tislelizumab in combination with sitravatinib achieved early antitumor activity and demonstrated a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics, Inc.

In women with advanced epithelial ovarian cancer treated in a single-institution study at the Cleveland Clinic, the addition of paclitaxel to cisplatin for hyperthermic intraperitoneal chemotherapy during interval debulking surgery was associated with improved oncologic outcomes compared with cisplatin alone.

Eric Pujade-Lauraine, MD, PhD, discussed PARP inhibitors and the benefits of various testing methods for HRD, in an interview with Targeted Oncology ahead of the Society of Gynecologic Oncology Annual Meeting on Women's Cancer.

The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.

Ursula A. Matulonis, MD, discusses the effect of the PARP inhibitor niraparib on recurrent ovarian cancer.

After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.

Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.

Olaparib maintenance continues to show clinical activity in platinum-sensitive ovarian cancer, including in patients with somatic BRCA mutations and non-BRCA homologous recombination repair mutations.

At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.

The addition of the investigational anti–PD-1 immunotherapy agent, dostarlimab, to niraparib and bevacizumab demonstrated positive antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.

Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.

The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.

A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.

Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.

During a Targeted Oncology Case-Based Peer Perspective event, Kathleen Moore, MD, discussed the combination of bevacizumab and olaparib as treatment of ovarian cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.